Cabaletta Bio (CABA) Projected to Post Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is projected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Cabaletta Bio to post earnings of ($0.66) per share for the quarter.

Cabaletta Bio Trading Up 6.7 %

NASDAQ:CABA opened at $1.91 on Thursday. The firm has a market capitalization of $93.36 million, a price-to-earnings ratio of -0.89 and a beta of 2.58. The firm’s fifty day simple moving average is $2.28 and its 200 day simple moving average is $3.27. Cabaletta Bio has a twelve month low of $1.59 and a twelve month high of $21.24.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CABA. Wells Fargo & Company lowered shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $12.00 to $6.00 in a report on Thursday, December 19th. William Blair reiterated an “outperform” rating on shares of Cabaletta Bio in a report on Monday, November 18th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a report on Tuesday, February 18th. Finally, Evercore ISI lowered shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and cut their price objective for the stock from $15.00 to $6.00 in a report on Friday, December 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $22.71.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.